<DOC>
	<DOCNO>NCT00397319</DOCNO>
	<brief_summary>To evaluate specific marker cardiovascular risk growth hormone replacement therapy population growth hormone deficient adult , compare age , gender , BMI-matched healthy population .</brief_summary>
	<brief_title>Growth Hormone 's Effect Cardiovascular System</brief_title>
	<detailed_description>Growth hormone deficiency ( GHD ) associate increased cardiovascular morbidity mortality . The effect deficiency include decrease exercise capacity tolerance , impaired cardiac function , central fat redistribution , increase peripheral arterial resistance , unfavorable lipid profile . These effect find reversed appropriate replacement therapy recombinant human growth hormone . We plan utilize several experimental system investigate role growth hormone ( GH ) maintain cardiovascular health . In particular , would like understand interaction GH Plasminogen-activator-inhibitor-1 ( major activator fibrinolytic system ) well role GH maintenance vascular function .</detailed_description>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Adult age 18 65 Documented Growth Hormone Deficiency define peak Growth Hormone GHRHArginine Stimulation test exceed 9.5 ng/ml Personal history cardiovascular disease ( previous myocardial infarction know coronary artery disease ) diagnosis heart disease study visit . Personal history diabetes mellitus development diabetes study visit . Initiation anticholesterol medication antihypertensive baseline followup study visit . Initiation regular tobacco use baseline followup study visit . Pregnancy nurse Current daily use drug know affect fibrinolytic system : Aspirin , Aggrenox , Plavix , Persantine , Ticlid , Pletal , Trental , Lovenox , Coumadin , Agrylin , Hydroxyurea .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>Growth Hormone</keyword>
	<keyword>Cardiovascular System</keyword>
</DOC>